Ultrasound-guided prostate biopsy: indication, morbidity and outcome at Hopital General Idrissa Pouye

• Main Authors: Modou Ndiaye, Mouhamed Jalloh, Madina Ndoye, Samba Thiapato Faye, Saint Charles Nabab Kouka, Ndiaga Seck Ndour, Mouhamadou Moustapha Mbodji, El Hadji Malick Diaw, Ibrahima Louis Mane, Issa Labou, Lamine Niang, Serigne Magueye Gueye
• Format: Article
• Language: English
• Published: SpringerOpen 2021-04-01
• Series: African Journal of Urology
• Subjects: Ultrasound; Biopsy; Prostate cancer; Morbidity
• Online Access: https://doi.org/10.1186/s12301-021-00155-9
• ISSN: 1110-5704; 1961-9987

Abstract Background Magnetic resonance imaging (MRI)-guided prostate biopsy has a higher sensitivity than the ultrasound-guided biopsy, but its realization requires a dedicated interventional MRI, specific material, which is not available in our context; hence, ultrasound-guided biopsy remains of great interest. Currently, ultrasound-guided biopsy outside of a clinical trial is the gold standard for the diagnosis of prostate cancer. The objective of our work is to evaluate our practice of transrectal ultrasound-guided prostate biopsy using an endorectal probe by describing the technique and evaluating the morbidity and results. Methods This is a descriptive study of ultrasound-guided prostatic biopsies performed over a 2-year period. The parameters studied were frequency of the procedure, age, rectal examination findings, total PSA level, prostate biopsy morbidities and results. Descriptive statistics were performed, and comparison of qualitative variables was made by the Chi-square test with statistical significance set for α < 5% Results Two hundred and thirty-one patients were included over a two-year period. The mean age of our patients was 65 ± 8.2 years. Rectal examination finding was suspicious in 36.9% and the median total PSA was 19.8 ng/ml (0.1-5936 ng/ml). Seventy-seven percent of patients reported their pathology results. Prostatic adenocarcinoma was the most common finding accounting for 53.7% of results. Complications were observed in 16 patients (6.9%) with a predominance of initial hematuria, voiding pain and fever. Conclusion In our series, the cancer detection rate was significant and the complications rate was acceptable at 6.9%.